Treatment of diabetes mellitus to reduce its chronic cardiovascular complications

Current Opinion in Cardiology

Volumn 13, Issue 2, 1998, Pages 131-138

  Savage, Peter J ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; LIPID;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; DIABETES CONTROL; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HEMOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW;

EID: 0031957878     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199803000-00010     Document Type: Review

References (39)

1. Portuese E, Orchard T: Mortality in insulin-dependent diabetes. In Diabetes in America, 2nd ed. Edited by National Diabetes Data Group, Bethesda, MD: National Institutes of Health, NIH Publication No. 95-1468; 1995:221-232.
2. Geiss LS, Herman WH, Smith PJ: Mortality in non-insulin dependent diabetes. In Diabetes in America, 2nd ed. Edited by National Diabetes Data Group, National Institutes of Health, NIH Publication No. 95-1468; 1995:233-258.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group: Diabetes, other risk factors, and 12 yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434-444.
4. Stern MP: Do non-insulin dependent diabetes mellitus and cardiovascular disease share common antecedents? Ann Intern Med 1996, 124(1 pt 2):110-116.
5. American Diabetes Association: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997, 20:1183-1197. New criteria for the classification and diagnosis of diabetes. Use of fasting glucose should facilitate screening for diabetes. Extensive discussion of reasons for change and relationship between new and old (1979) criteria.
6. Dagogo-Jack S, Santiago JV: Pathophysiology of Type 2 diabetes and modes of action of therapeutic interventions. Arch Intern Med 1997, 157:1802-1817. An excellent review of current treatment options for Type 2 diabetes. Comments on the potential benefit of reducing insulin resistance need to be considered in the light of recent fragmentary reports of liver toxicity in troglitazone-treated patients.
7. Meigs JB, Singer DE, Sullivan LM, Dukes KA, D'Agostino RB, Nathan DM, Wagner EH, Kaplan SH, Greenfield S: Metabolic control and prevalent cardiovascular disease in non-insulin dependent diabetes mellitus (NIDDM): the NIDDM patient outcomes research team. Am J Med 1997, 102:38-47. Major gaps exist in research on the cost and effectiveness of diabetes care. This report attempts to identify the most beneficial treatments.
8. American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 1997, 20(suppl 1):S5-S13. An attempt by the ADA to define basic medical care standards for people with diabetes (updated frequently).
9. Harris MI: Medical care for patients with diabetes. Ann Intern Med 1996, 124(1 pt 2):117-122. Note major discrepancies between recommended care and what has been achieved.
10. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993, 269:3015-3023.
11. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997, 157:2413-2446, Updated guidelines for detection and treatment of hypertension; includes discussion of special needs of diabetic patients.
12. The Diabetes Control and Complications Trial Research Group: The effect of the intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
13. Diabetes Drafting Group: WHO multinational study of vascular disease in diabetics-prevalence of small vessel and large vessel disease in diabetic patients from 14 centers. Diabetologia 1985, 28:615-640.
14. U.K. Prospective Diabetes Study Group: U.K. Prospective Diabetes Study 16 - overview of 6 years' therapy of Type 2 diabetes: a progressive disease. Diabetes 1995, 44:1249-1258.
15. Howard BV, Howard WJ: Dyslipidemia in non-insulin dependent diabetes mellitus. Endocrine Rev 1994, 15:263-274.
16. Stern MP, Mitchell BD, Haffner SM, Hazuda HP: Does glycemic control of Type 2 diabetes suffice to control diabetic dyslipidemia? Diabetes Care 1992, 15:638-644.
17. American Diabetes Association Consensus Statement: Detection and management of lipid disorders in diabetes. Diabetes Care 1993, 16(suppl 2):106-113.
18. Pyorala K, Pedersen PR, Kjekshus J, Faergeman O, Olsson AG, Thorgriersson G: The Scandinavian Simvastatin Study Group: cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997, 20:614-620. An important study that demonstrated the benefit of cholesterol reduction on coronary heart disease in diabetic patients. Note that this benefit is greater than any benefit shown to date for control of hyperglycemia on macrovascular complications.
19. Haffner SM: Scandinavian Simvastatin Survival Study subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease [editorial]. Diabetes Care 1997, 20:469-471.
20. Grossman E, Messerli FH: Diabetic and hypertensive heart disease. Ann Intern Med 1996, 125:304-310.
21. Curb JD, Stamler J, Rutan GH, Oberman A, Guthrie G, Gonzalez N, Frost PH, Davis BR, Camel G, Black H, et al:. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension: Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996, 276:1886-1892.
22. Estacio RO, Savage S, Nagel NJ, Schrier RW: Baseline characteristics of participants in the appropriate blood pressure control in diabetes trial. Controlled Clin Trials 1996, 17:242-257.
23. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, Grimm RC, LaRosa J, Welton PK, Perry HM, et al., for the ALLHAT Research group: Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). Am J Hypertens 1996, 9:342-360. ALLHAT is a large clinical trial that will provide important answers to many questions about the relative value of different antihypertensive drugs in diabetic hypertensive patients.
24. Hsueh W, Law RE, Saad M, Dy J, Feener E, King G: Insulin resistance and macrovascular disease. Curr Opin Endocrinol Diabetes 1996, 3:346-354.
25. Wingard DL, Barrett-Connor EL, Ferara A: Is insulin really a heart disease risk factor? Diabetes Care 1995, 18:1299-1304.
26. Reaven GM: Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
27. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, Bergman R, for the IRAS investigators: Insulin sensitivity and atherosclerosis. Circulation 1996, 93:1809-1817.
28. Reaven GM: Role of Insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 1993, 44:121-131.
29. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and Type 2 diabetes. Diabetes 1996, 45:1661-1669.
30. Food and Drug Administration (FDA) Talk Paper T97-61 (12-1-97). Available at FDA Internet site http://www.fda.gov/bbs/topics/ANSWERS/ANS00837.html. New updates on this evolving issue are available at the main FDA Internet site. Go to MedWatch and look under Safety Information.
31. Ridker PM, Hennekens CH: Hemostatic risk factors for coronary heart disease. Circulation 1991, 83:1098-1100.
32. ETDRS investigators: Aspirin effects on mortality and morbidity in patients with diabetes mellitus: early treatment diabetic retinopathy study report 14. JAMA 1992, 268:1292-1300.
33. Antiplatelet Trialists' Collaboration Group: Collaborative overview of randomized trials of antiplatelet therapy - I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Bri Med J 1994, 308:81-106.
34. Steering Committee of the Physicians' Health Study Research Group: Final report on the aspirin component of the ongoing physicians' health study. N Engl J Med 1989, 321:129-135.
35. Aronson D, Rayfield EJ, Chesebro JH: Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med 1997, 126:296-306.
36. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, Wedel H: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at one year. J Am Coll Cardiol 1995, 26:57-65.
37. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators: Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996, 335:217-225.
38. Gundersen T, Kjekshus J: Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care 1983, 6:285-290.
39. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, Clegg LX: Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors. The Atherosclerosis Risk in Community (ARIC) study, 1987-1993. Am J Epidemiol 1997, 146:483-494.